Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 7/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.33 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16231925 | 0.90 | GPR84 (0.43) | DAOAURKBNOTUMGPR84CYP1A2 | |
| SCHEMBL14719044 | 0.89 | DAO (0.50) | DAOAURKBGPR84TIPARPENPP1 | |
| SCHEMBL14719586 | 0.86 | DAO (0.52) | DAOP2RX7TIPARPENPP1 | |
| SCHEMBL30159699 | 0.85 | DAO (0.53) | DAONOTUMMGLLTIPARPFLT1 | |
| SCHEMBL14718624 | 0.85 | DAO (0.53) | DAONOTUMMGLLTIPARPFLT1 | |
| SCHEMBL16231992 | 0.84 | DAO (0.49) | DAO | |
| SCHEMBL16231932 | 0.84 | NR3C2 (0.45) | DAOP2RX7ENPP1 | |
| SCHEMBL16231912 | 0.84 | PARP1 (0.45) | DAO | |
| SCHEMBL16231905 | 0.81 | DAO (0.41) | DAO | |
| Luvadaxistat SCHEMBL14719667 | 0.81 | DAO (0.48) | DAOGPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-13 | — | — | US | disclosed |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-09-28 | — | — | US | disclosed |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-11-05 | — | — | US | disclosed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | disclosed |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-06-28 | — | — | US | disclosed |
| US-9931340-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-03 | — | — | US | disclosed |
| US-9931340-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-03 | — | — | US | disclosed |
| EP-2748149-B9 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2017-11-15 | — | — | EP | disclosed |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-06-22 | — | — | US | disclosed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | disclosed |
| US-9290456-B2 | Pyridazinone compounds and their use as DAAO inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-03-22 | — | — | US | disclosed |
| EP-2748149-B1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL (JP) | 2015-10-21 | — | — | EP | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-29 | — | — | US | disclosed |
| WO-2013027000-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | WO | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20130052281-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130052281-A1 | NOVEL COMPOUNDS | ABCG2, F12, UGT1A1 | DAO 4565/4885AURKB 2610/4885PHGDH 3588/4885 |
| US-20150030704-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885AURKB 2434/4885PHGDH 757/4885 |
| US-11129828-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885AURKB 2434/4885PHGDH 757/4885 |
| US-20180177780-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885AURKB 2434/4885PHGDH 757/4885 |
| US-10463663-B2 | Pyridazinone compounds and their use as DAAO inhibitors | PNPO, DAO, DPYD | DAO 2/4885AURKB 2434/4885PHGDH 757/4885 |
| US-20170173007-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885AURKB 2434/4885PHGDH 757/4885 |
| US-20220008416-A1 | PYRIDAZINONE COMPOUNDS AND THEIR USE AS DAAO INHIBITORS | PNPO, DAO, DPYD | DAO 2/4885AURKB 2434/4885PHGDH 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.